Navigation Links
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Date:4/22/2008

statistically significant 50 percent reduction in late loss compared to

TAXUS (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS).

-- Statistical non-inferiority to TAXUS in the major secondary

(co-primary) endpoint of target vessel failure (TVF) at nine months.

XIENCE V demonstrated an observed 20 percent reduction in TVF compared

to TAXUS (7.2 percent for XIENCE V vs. 9.0 percent for TAXUS). TVF is a

composite clinical measure of safety and efficacy outcomes defined as

cardiac death, heart attack (myocardial infarction or MI) or target

vessel revascularization (TVR).

-- An observed 43 percent reduction in the pre-specified secondary

endpoint of major adverse cardiac events (MACE) at nine months

(4.6 percent for XIENCE V vs. 8.1 percent for TAXUS) and an observed

42 percent reduction in MACE at one year (6.0 percent for XIENCE V vs.

10.3 percent for TAXUS) compared to TAXUS. MACE is an important

composite clinical measure of safety and efficacy outcomes for

patients, defined as cardiac death, heart attack (MI), or

ischemia-driven target lesion revascularization (TLR driven by lack of

blood supply).

"The low rate of MACE seen with XIENCE V in the SPIRIT III trial can be directly attributed to fewer patients experiencing heart attacks or re-treatment, and is consistent with data from previous trials," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs and chief medical officer, Abbott Vascular. "Superior efficacy combined with increased flexibility and deliverability reinforce that XIENCE V is a significant advancement in stent technology that will be a welcome addition to the field of interventional cardiology."

Additional Results from SPIRIT III

There were no significant differences between XIENCE V and TAXUS in the rates of stent thrombosis either early (less than or
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
2. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
3. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
4. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
5. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
8. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
9. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses on ... the United States . Reimbursement analysis ... Thorough product analyses for more than 73 SMBG meters ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... which suggests hormone suppression therapy could increase substantially ... free of the disease.Michel Bolla, a professor at ... suppressing the male hormone androgen, similar to the ... patients in advanced stages// of their prostate cancer, ...
... a good amount of fluids should be taken, in order ... far better than 'energy' drinks for keeping you hydrated during ... you'll be well aware of the need to keep your ... lot of so-called energy drinks around, which seem to promise ...
... proteins, which are protective substances, produced by the body ... the TB bacteria, researchers in the UK report. According ... journal Nature Medicine,// these heat-shock proteins, which are special ... times and bolster the immune system of the body. ...
... According to new study, a new type of antidepressant, ... anxiety disorder (SAD) people experience fear, anxiety and dread ... which can make both work //and social situations a ... mental health problems, like depression, and the condition can ...
... at the University of Texas, have shown that use of ... to 70 per cent of US women born since 1950 ... that use of the hormones in the Pill could raise ... failed to reveal a connection. The early Pill users are ...
... at the University of Texas has found that caffeine ... in preterm infants. Sleep apnea is a condition characterized ... infants. However, there is a growing concern over caffeine's ... Texas analyzed the effects of caffeine on cardiac output, ...
Cached Medicine News:Health News:Hormone Therapy applicable for Prostate Cancer 2Health News:Caffeine reduces infant blood flow 2
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide smooth handle with polished finish....
Smooth 90 degree jaws with locking screw maintain proper stretch of sleeve for securing silicone bands....
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 ga. shaft tapering to 23 ga., 10 mm from tip. Overall length from rear rotation knob to tip....
Medicine Products: